Skip to main content

Menu

Select a tool from the sidebar

Create your free account now!

Sign in to customize and use tools on the sidebar.

Sign InCreate free account
Laboratorios Farmaceuticos Rovi, S.A. logo
ROVI.MC
Laboratorios Farmaceuticos Rovi, S.A.
13:10:38
58.1 €
0.0000 (%0.00)
Previous Close: 58.3
Day Low₺58
Day High₺58.55
Bid
Ask
Overview
Technicals
Financial Statements
Comments
Archive

ROVI.MC: Laboratorios Farmaceuticos Rovi, S.A. Financials

Laboratorios Farmaceuticos Rovi, S.A. Income Statement

Total revenue
Net income
Gross margin TTM
60.75%
Operating margin TTM
23.29%
Net profit margin TTM
18.89%
Return on investment TTM
21.14%
Period end31/12/202531/12/202431/12/202331/12/2022
Total revenue743,483,000763,749,000829,509,000817,698,000
Operating income173,143,000179,545,000220,254,000255,848,000
Net income140,442,000136,881,000170,335,000199,669,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Total revenue743,483,000763,749,000829,509,000817,698,000
Cost of revenue291,831,000285,403,000346,165,000298,085,000
Gross profit451,652,000478,346,000483,344,000519,613,000
Research and development expenses37,796,00025,752,000023,869,000
General and administrative expenses017,688,000125,269,00012,782,000
Selling and marketing expenses021,737,00021,754,00019,993,000
Selling, general and administrative expenses232,831,00039,425,000147,023,00032,775,000
Other expenses7,882,000259,376,000116,067,000243,770,000
Operating expenses278,509,000298,801,000263,090,000263,763,000
Cost and expenses570,340,000584,204,000609,255,000561,848,000
Net interest income-2,341,000-2,324,000-941,000-843,000
Interest income505,00026,0007,0006,000
Interest expense2,846,0002,350,000941,000849,000
Depreciation and amortization30,374,00028,015,00024,331,00022,871,000
EBITDA203,517,000207,693,000245,812,000281,488,000
EBIT173,143,000179,678,000221,356,000258,573,000
Non-operating income (excl. interest)0-133,000-1,102,000-2,725,000
Operating income173,143,000179,545,000220,254,000255,848,000
Total other income/expenses (net)10,120,000-1,855,000154,0001,920,000
Income before tax183,263,000177,690,000220,408,000257,967,000
Income tax expense42,899,00040,814,00050,109,00058,302,000
Net income from continuing operations140,364,000137,017,000170,299,000199,665,000
Net income from discontinued operations0000
Other adjustments to net income0-141,00000
Net income140,442,000136,881,000170,335,000199,669,000
Net income deductions0000
Bottom line net income140,442,000136,881,000170,335,000199,669,000
EPS3334
Diluted EPS3334
Weighted average shares outstanding51,146,00051,266,29251,820,14653,466,000
Weighted average diluted shares outstanding51,146,00051,266,29251,820,14653,466,000

Laboratorios Farmaceuticos Rovi, S.A. Balance Sheet

Total assets
Total liabilities & equity
Liquidity ratio MRQ
—
Current ratio MRQ
—
Long-term debt / assets MRQ
93,204,000%
Total debt / assets MRQ
—
Period end31/12/202531/12/202431/12/202331/12/2022
Total assets955,691,000832,022,000799,884,000878,703,000
Total liabilities276,793,000250,482,000256,390,000357,324,000
Total equity664,415,000572,028,000539,387,000520,012,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Cash and cash equivalents97,976,00027,186,00025,322,000124,945,000
Short-term investments0227,00000
Cash and short-term investments97,976,00027,413,00025,322,000124,945,000
Net receivables177,569,000129,502,000143,314,000184,159,000
Accounts receivable163,314,000114,827,000143,314,000180,011,000
Other receivables14,255,00014,644,00004,148,000
Inventory287,975,000329,954,000337,968,000311,944,000
Prepaid expenses3,188,0002,687,0002,727,0002,025,000
Other current assets2,950,0002,019,0001,793,0004,148,000
Total current assets569,658,000491,575,000509,331,000623,073,000
Property, plant and equipment (net)330,735,000286,622,000253,652,000215,541,000
Goodwill2,702,000000
Intangible assets33,183,00033,950,00033,902,00035,744,000
Goodwill and intangible assets35,885,00033,950,00033,902,00035,744,000
Long-term investments19,164,00019,289,000591,0002,267,000
Tax assets249,0002,263,0002,343,0002,078,000
Other non-current assets0292,000130,0000
Total non-current assets386,033,000342,416,000290,553,000255,630,000
Other assets0-1,969,00000
Total assets955,691,000832,022,000799,884,000878,703,000
Total payables72,666,000120,191,000109,601,000125,872,000
Accounts payable68,233,00086,851,000107,593,000123,901,000
Other payables4,433,00033,340,0002,008,0001,971,000
Accrued expenses7,685,000030,766,00031,672,000
Short-term debt43,553,00017,842,0008,060,0008,238,000
Capital lease obligations (current)05,849,0005,125,0004,459,000
Tax payables02,384,0005,255,00041,000
Deferred revenue4,042,00000114,901,000
Other current liabilities53,307,00012,769,00046,291,000123,646,000
Total current liabilities181,253,000156,651,000199,843,000293,887,000
Long-term debt93,204,00080,503,00038,575,00046,044,000
Capital lease obligations (non-current)9,328,00010,216,00013,667,00013,397,000
Deferred revenue (non-current)2,016,0002,746,0002,790,0003,319,000
Deferred tax liabilities (non-current)129,000366,0001,515,000677,000
Other non-current liabilities-9,137,000000
Total non-current liabilities95,540,00093,831,00056,547,00063,437,000
Other liabilities0000
Capital lease obligations9,328,00016,065,00018,792,00017,856,000
Total liabilities276,793,000250,482,000256,390,000357,324,000
Treasury stock-5,174,000-5,545,000-107,676,000-27,561,000
Preferred stock0000
Common stock3,074,0003,074,0003,241,0003,241,000
Retained earnings578,260,000486,213,000555,534,000456,031,000
Additional paid-in capital87,636,00087,636,00087,636,00087,636,000
Accumulated other comprehensive income/loss619,000650,000652,000665,000
Other stockholders' equity0000
Total stockholders' equity664,415,000572,028,000539,387,000520,012,000
Total equity675,455,000581,540,000543,494,000521,379,000
Minority interest11,040,0009,512,0004,107,0001,367,000
Total liabilities and total equity955,691,000832,022,000799,884,000878,703,000
Total investments19,164,00019,516,000591,0002,267,000
Total debt146,085,000114,410,00065,427,00072,138,000
Net debt48,109,00087,224,00040,105,000-52,807,000

Laboratorios Farmaceuticos Rovi, S.A. Cash Flow Statement

Cash from operations
Cash from investing
Cash flow / share TTM
—
Revenue / share TTM
—
Operating cash flow TTM
—
Period end31/12/202531/12/202431/12/202331/12/2022
Cash from operations185,372,000138,278,000113,247,000237,602,000
Cash from investing-67,561,000-81,058,000-52,028,000-57,154,000
Cash from financing-47,021,000-55,356,000-160,842,000-154,537,000
Net change in cash70,790,0001,864,000-99,623,00025,910,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Net income140,442,000177,690,000220,408,000257,967,000
Depreciation and amortization30,374,00028,015,00024,331,00022,871,000
Deferred income tax0000
Stock-based compensation0000
Change in working capital-12,752,0008,960,000-10,525,000-56,973,000
Accounts receivable-30,185,00013,410,00019,471,000-26,820,000
Inventory42,988,00011,871,000-29,294,000-71,591,000
Accounts payable-7,749,000-16,361,000-23,923,00041,672,000
Other working capital-17,806,00040,00023,221,000-234,000
Other non-cash items27,308,000-76,387,000-120,967,00013,737,000
Net cash from operating activities185,372,000138,278,000113,247,000237,602,000
Investments in property, plant and equipment-67,813,000-62,219,000-53,794,000-51,388,000
Acquisitions (net)1,651,000-19,090,0001,200,00078,000
Purchases of investments-3,463,00000-5,870,000
Sales/maturities of investments080,00088,00020,000
Other investing activities2,064,000171,000478,0006,000
Net cash from investing activities-67,561,000-81,058,000-52,028,000-57,154,000
Net debt issuance818,00045,241,000-12,920,000-5,369,000
Long-term net debt issuance045,241,000-12,920,000-5,369,000
Short-term net debt issuance818,000000
Net stock issuance-9,000-47,787,000-81,261,000-99,242,000
Net common stock issuance-9,000-47,787,000-81,261,000-99,242,000
Common stock issuance54,851,00041,921,00052,639,00077,766,000
Common stock repurchased-54,860,000-89,708,000-133,900,000-177,008,000
Net preferred stock issuance0000
Net dividends paid-47,830,000-56,451,000-69,049,000-51,007,000
Common dividends paid-47,830,000-56,451,000-69,049,000-51,007,000
Preferred dividends paid0000
Other financing activities03,641,0002,388,0001,080,000
Net cash from financing activities-47,021,000-55,356,000-160,842,000-154,537,000
Effect of FX changes on cash000-1,000
Net change in cash70,790,0001,864,000-99,623,00025,910,000
Cash at end of period97,976,00027,186,00025,322,000124,945,000
Cash at beginning of period27,186,00025,322,000124,945,00099,035,000
Operating cash flow185,372,000138,278,000113,247,000237,602,000
Capital expenditure-65,210,000-62,219,000-55,187,000-51,388,000
Free cash flow120,162,00076,059,00058,060,000186,214,000
Income taxes paid0000
Interest paid0000